The Jordanian Pharmaceutical Manufacturing Company - Public Shareholding Company (ASE:JPHM)
Jordan
· Delayed Price · Currency is JOD 1.520
-0.010 (-0.65%)
At close: Apr 28, 2026
ASE:JPHM Income Statement
Financials in millions JOD. Fiscal year is January - December.
Millions JOD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Revenue | 24.46 | 16.86 | 14.58 | 16.96 | 15.83 | 14.92 | Upgrade
|
| Revenue Growth (YoY) | 63.74% | 15.65% | -14.03% | 7.16% | 6.12% | 49.49% | Upgrade
|
| Cost of Revenue | 12.06 | 9.78 | 11.01 | 10.11 | 10.79 | 9.93 | Upgrade
|
| Gross Profit | 12.4 | 7.08 | 3.57 | 6.86 | 5.04 | 4.99 | Upgrade
|
| Selling, General & Admin | 5.89 | 5.76 | 4.99 | 5.44 | 7.21 | 7.95 | Upgrade
|
| Research & Development | 0.34 | 0.36 | 0.48 | 0.47 | 0.41 | - | Upgrade
|
| Amortization of Goodwill & Intangibles | 0.06 | 0.06 | 0.04 | 0.04 | 0.03 | 0.04 | Upgrade
|
| Other Operating Expenses | 0.61 | 0.61 | 0.06 | 0.42 | - | - | Upgrade
|
| Operating Expenses | 6.9 | 6.79 | 5.58 | 7.73 | 7.65 | 7.98 | Upgrade
|
| Operating Income | 5.5 | 0.29 | -2.01 | -0.88 | -2.61 | -2.99 | Upgrade
|
| Interest Expense | -0.3 | -0.39 | -0.65 | -1.32 | -0.93 | -1.48 | Upgrade
|
| Earnings From Equity Investments | 0.84 | 1.51 | 0.23 | 1.26 | -0.11 | 0.15 | Upgrade
|
| Currency Exchange Gain (Loss) | - | - | -0.08 | -0.06 | -0 | -0.02 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.12 | -0.34 | -0.13 | 0.18 | 0.01 | 0.01 | Upgrade
|
| EBT Excluding Unusual Items | 5.92 | 1.06 | -2.63 | -0.83 | -3.64 | -4.33 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | -0.03 | - | 0.02 | Upgrade
|
| Asset Writedown | -0.06 | -0.08 | -0.07 | -0.07 | -0.07 | -0.09 | Upgrade
|
| Legal Settlements | - | - | - | - | 2.83 | -5.67 | Upgrade
|
| Other Unusual Items | - | - | - | - | 1.03 | 0.49 | Upgrade
|
| Pretax Income | 5.87 | 0.98 | -2.71 | -0.92 | 0.15 | -9.58 | Upgrade
|
| Income Tax Expense | 1 | 0.34 | 0.14 | -1.14 | 0.06 | 2.1 | Upgrade
|
| Earnings From Continuing Operations | 4.87 | 0.64 | -2.85 | 0.22 | 0.09 | -11.68 | Upgrade
|
| Minority Interest in Earnings | -0 | 0.01 | -0 | 0 | 0.03 | 0.05 | Upgrade
|
| Net Income | 4.86 | 0.65 | -2.86 | 0.22 | 0.12 | -11.64 | Upgrade
|
| Net Income to Common | 4.86 | 0.65 | -2.86 | 0.22 | 0.12 | -11.64 | Upgrade
|
| Net Income Growth | - | - | - | 79.58% | - | - | Upgrade
|
| Shares Outstanding (Basic) | 34 | 34 | 34 | 69 | 69 | 25 | Upgrade
|
| Shares Outstanding (Diluted) | 34 | 34 | 34 | 69 | 69 | 25 | Upgrade
|
| Shares Change (YoY) | -51.69% | - | -50.83% | - | 170.77% | - | Upgrade
|
| EPS (Basic) | 0.14 | 0.02 | -0.08 | 0.00 | 0.00 | -0.46 | Upgrade
|
| EPS (Diluted) | 0.14 | 0.02 | -0.08 | 0.00 | 0.00 | -0.46 | Upgrade
|
| EPS Growth | - | - | - | 79.56% | - | - | Upgrade
|
| Free Cash Flow | 4.26 | 0.98 | 0.4 | -6.59 | -0.32 | -9.66 | Upgrade
|
| Free Cash Flow Per Share | 0.13 | 0.03 | 0.01 | -0.10 | -0.01 | -0.38 | Upgrade
|
| Gross Margin | 50.68% | 42.00% | 24.51% | 40.42% | 31.85% | 33.45% | Upgrade
|
| Operating Margin | 22.48% | 1.71% | -13.77% | -5.17% | -16.48% | -20.07% | Upgrade
|
| Profit Margin | 19.88% | 3.86% | -19.59% | 1.29% | 0.77% | -78.02% | Upgrade
|
| Free Cash Flow Margin | 17.43% | 5.82% | 2.75% | -38.88% | -2.02% | -64.79% | Upgrade
|
| EBITDA | 6.13 | 1.08 | -1.41 | -0.37 | -2.19 | -2.56 | Upgrade
|
| EBITDA Margin | 25.05% | 6.41% | -9.66% | -2.19% | -13.82% | -17.13% | Upgrade
|
| D&A For EBITDA | 0.63 | 0.79 | 0.6 | 0.51 | 0.42 | 0.44 | Upgrade
|
| EBIT | 5.5 | 0.29 | -2.01 | -0.88 | -2.61 | -2.99 | Upgrade
|
| EBIT Margin | 22.48% | 1.71% | -13.77% | -5.17% | -16.47% | -20.07% | Upgrade
|
| Effective Tax Rate | 17.05% | 34.57% | - | - | 37.93% | - | Upgrade
|
| Advertising Expenses | - | 0.24 | 0.1 | 0.14 | 0.32 | 0.58 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.